Vanda gets EU orphan designation for imsidolimab in pustular psoriasis
Vanda Pharmaceuticals says the European Commission granted orphan designation for imsidolimab for the treatment of generalized pustular psoriasis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.